Home  >  Research  >  Labs  >  Cancer Program  >  CANCER MICROENVIRONMENT

RESEARCH OVERVIEW

We are interested in the cancer microenvironment or tumour stroma which consists of various cell types, including immune cells and blood vessels, and supports cancer growth. Our research program aims to understand how stromal cells are remodelled, and the extent to which stromal networks regulate cancer progression. We have shown that the tumour microenvironment is highly dynamic and can be re-programmed or remodelled to enhance immune cell uptake and overall response to immunotherapy. Furthermore, we have developed precision tools to specifically target abnormal stromal features to disrupt and re-program signalling networks between multiple stromal components and to break the vicious cycle of disease progression and relapse.

Utilising a suite of preclinical cancer models which includes genetically modified mouse models of pancreatic cancers, orthotopic cancer models of breast, lung, brain and melanoma, and human cancer specimens our goal is to develop new drugs that can increase the survival rate and quality of life of cancer patients.

Professor Ruth Ganss

Professor Ruth Ganss

Cancer Microenvironment

Read more

LATEST NEWS

Researchers discover blood markers that could predict mesothelioma treatment success

A groundbreaking study by researchers at the National Centre for Asbestos Related Diseases (NCARD), The Kids Research Institute and the Harry Perkins Institute of Medical Research (the Perkins) has identified blood markers that could help predict how well mesothelioma patients respond to treatment. This discovery could transform how treatment decisions…

Read More

$10 million raised for WA Cancer Research

West Australians give record amount in Australia’s biggest charity ride.  This morning it was announced a record $10,104,999 has been raised for WA cancer research by the nation’s biggest charity bike ride, the MACA Cancer 200 Ride for Research.  The funds raised will go to Perth’s Harry Perkins Institute of…

Read More

Lowering cancer drug dose could open tumours to immunotherapy

Groundbreaking research undertaken at the Harry Perkins Institute of Medical Research in Perth has shown that administering anti-cancer drugs at a hundred-fold lower dose than standard protocols could improve the tumour’s response to immunotherapy.  Perkins Head of Cancer Microenvironment, Professor Ruth Ganss from The University of Western Australia (UWA), said…

Read More